Sorrento Therapeutics (SRNE -1.4%) inks an agreement with
the University of Texas Medical Branch (UTMB) at Galveston for the
preclinical testing of its COVID-19 therapeutic candidates using an
infection cell model for SARS-CoV-2. The testing will be conducted in a
Biosafety Level 4 (maximum containment) laboratory at UTMB, one of only
two on a university campus in the U.S., since it will be working with a
COVID-19 viral isolate.
The company says it has a range of preclinical
candidates across its platforms, including natural killer (NK) cell
therapies, neutralizing antibodies (NAbs) and soluble recombinant fusion
protein traps (COVIDTRAP) to potentially inhibit the binding of
SARS-CoV-2’s spike protein with host ACE2 receptors on the surface of
cells, thereby potentially preventing the first step in the infection
process.
https://seekingalpha.com/news/3556953-sorrento-to-test-covidminus-9-candidates-in-infection-cell-model-live-virus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.